News | July 02, 2012

Six-minute Walk Stress Echo is Practical, Cost-effective to Evaluate Patients With Connective Tissue Disease

July 2, 2012 — Researchers have announced the results of a study that shows the utility of a six minute walk stress echocardiogram for the early detection of exercise-induced pulmonary arterial hypertension (EIPAH) in patients with connective tissue disease (CTD). Earlier treatment of these patients may improve the prognosis for CTD, as those who develop EIPAH may be at risk for resting pulmonary arterial hypertension (PAH) in the future.

A poster based on the study will be presented on Sunday, July 1 from 9:30 a.m. to 4:30 p.m. in the exhibit and poster hall during the American Society of Echocardiography (ASE) 23rd Annual Scientific Sessions. Investigators will be available in the hall from 12:15 p.m. to 1:45 p.m. The ASE Scientific Sessions will be held from June 27 to July 3, 2012, at the Gaylord National in National Harbor, MD.

“Doppler echocardiography is currently the recommended screening modality to diagnose PAH; however, in about two-thirds of cases, the pulmonary vascular bed had been already impaired in patients diagnosed to have PAH at rest. To diagnose PAH earlier, it is helpful to detect exercise-induced PAH (EIPAH) by stress echocardiography. Our study shows the efficacy of 6-minute walk stress echocardiography for this purpose. In our study, we were able to detect EIPAH in CTD patients who did not have PAH when at rest. Six-minute walk stress echocardiography is an easy, inexpensive and useful tool for detecting EIPAH, which could be very early-stage PAH,” said primary investigator Junko Hotchi.

Hirotsugu Yamada, Susumu Nishio, Noriko Tomita, Shuji Hayashi, Mika Bando, Rina Tamai, Maya Nakagawa, Daichi Hirota, Yukina Hirata, Kozue Ogasawara, Sachiko Bando, Takayuki Ise, Toshiyuki Niki, Koji Yamaguchi, Yoshio Taketani, Takashi Iwase, Takeshi Soeki, Tetsuzo Wakatsuki, and Masataka Sata, all of Tokushima University Hospital, Tokushima, Japan, and Kenya Kusunose of the Cleveland Clinic, Cleveland, were also part of the team that conducted the study, which found EIPAH in 29 out of a 109 patient study group.

For more information: www.asecho.org


Related Content

News | Cardiovascular Clinical Studies

Nov. 18, 2024 — Silence Therapeutics presented end-of-treatment data from its Phase 2 ALPACAR-360 study of zerlasiran, a ...

Home November 18, 2024
Home
News | Cardiovascular Clinical Studies

Aug. 15, 2024 — According to a new study being presented at ACC Asia 2024 in Delhi, India, drinking over 400 mg of ...

Home August 14, 2024
Home
Videos | Cardiovascular Clinical Studies

As part of DAIC's continuing Thought Leadership Series, this month Editorial Director Melinda Taschetta-Millane sits ...

Home July 30, 2024
Home
News | Cardiovascular Clinical Studies

July 25, 2024 — BioCardia, Inc., a global leader in cellular and cell-derived therapeutics for the treatment of ...

Home July 25, 2024
Home
News | Cardiovascular Clinical Studies

July 18, 2024 — Elucid, a pioneering AI medical technology company providing physicians with imaging analysis software ...

Home July 18, 2024
Home
News | Cardiovascular Clinical Studies

July 10, 2024 — CellProthera, a private company specializing in cell-based therapies for repairing ischemic tissues, and ...

Home July 10, 2024
Home
News | Cardiovascular Clinical Studies

July 9, 2024 — Microbot Medical Inc. announced the completion of the first procedure in a patient utilizing its LIBERTY ...

Home July 09, 2024
Home
News | Cardiovascular Clinical Studies

June 26, 2024 — Semaglutide, a medication initially developed for type 2 diabetes and obesity, significantly improves ...

Home June 26, 2024
Home
News | Cardiovascular Clinical Studies

June 21, 2024 — Lexicon Pharmaceuticals, Inc. announced that the peer-reviewed Journal of the American College of ...

Home June 21, 2024
Home
News | Cardiovascular Clinical Studies

June 20, 2024 — Microbot Medical Inc. announced its agreement with Brigham and Women’s Hospital (BWH), a leading ...

Home June 20, 2024
Home
Subscribe Now